National Pension Service Acquires 46,936 Shares of Bristol Myers Squibb Company $BMY

National Pension Service increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 0.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,578,135 shares of the biopharmaceutical company’s stock after purchasing an additional 46,936 shares during the quarter. National Pension Service owned approximately 0.27% of Bristol Myers Squibb worth $321,412,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its holdings in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC grew its position in shares of Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares in the last quarter. United Bank increased its holdings in shares of Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Bristol Myers Squibb in the second quarter worth about $221,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth about $405,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BMY shares. TD Cowen started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating for the company. Sanford C. Bernstein raised Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Wells Fargo & Company set a $65.00 target price on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a report on Friday, July 31st. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Jefferies Financial Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising arlo-cel multiple myeloma results: Bristol Myers reported positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, or arlo-cel, a potential first-in-class GPRC5D-directed CAR-T therapy. The results could strengthen BMY’s position in heavily pretreated multiple myeloma and expand its growth pipeline. Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial
• Positive Sentiment: Pipeline diversification opportunity: Analysts characterized the arlo-cel data as a potentially important addition to Bristol Myers’ cell-therapy portfolio. Success could eventually provide another commercial product to offset patent-expiration and competitive pressures affecting parts of the company’s existing portfolio. Will the Recent Pipeline Progress Boost BMY’s Portfolio Expansion?
• Neutral Sentiment: SOTYKTU growth potential: An industry report sees additional opportunities for BMY’s SOTYKTU in earlier-line treatment, injection-averse patients and new immune-mediated indications. The report is commercially supportive but does not represent a new company announcement or regulatory approval. SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
• Negative Sentiment: CAR-T safety concerns are weighing on the sector: Novartis paused eight experimental CAR-T trials after three patient deaths linked to severe immune reactions. Although the issue involves Novartis, it may increase investor scrutiny of cell-therapy safety, development costs and regulatory risks for BMY’s arlo-cel program. Could Bristol-Myers Squibb Outperform Novartis as CAR-T Safety Concerns Shake the Sector?
• Negative Sentiment: Investors initially sold the news: Reports indicate BMY shares moved lower despite the arlo-cel trial success, suggesting investors may be taking profits or focusing on unanswered questions around safety, approval timing and the therapy’s eventual commercial potential. Bristol-Myers Squibb Stock Heads Into the Open After a 3.2 Percent Drop

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $64.46 on Thursday. The stock has a market cap of $131.68 billion, a price-to-earnings ratio of 14.20, a price-to-earnings-growth ratio of 0.31 and a beta of 0.23. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a 50 day moving average price of $63.39 and a 200-day moving average price of $60.03. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. During the same period last year, the company earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.